

Brompton Global Healthcare Income & Growth ETF
Summary of Investment Portfolio as at December 31, 2021

Total Net Asset Value \$ 79,526,817

Portfolio Composition	% of Net Asset Value
Europe	
Denmark	
Pharmaceuticals	4.5%
Germany	
Pharmaceuticals	3.9%
Healthcare Equipment	1.9%
Great Britain	
Pharmaceuticals	5.7%
Ireland	
Healthcare Equipment	4.1%
Switzerland	
Healthcare Equipment	5.7%
Total Europe	25.8%
North America	
United States	
Healthcare Equipment	22.9%
Pharmaceuticals	17.3%
Life Sciences Tools and Services	15.2%
Managed Healthcare	4.3%
Healthcare Supplies	3.9%
Healthcare Facilities	3.8%
Biotechnology	3.3%
Healthcare Services	3.3%
Total North America	74.0%
Cash and short-term investments	0.6%
Other net liabilities	(0.4%)
Total Net Asset Value	100.0%

Top 25 Holdings	% of Net Asset Value
Novo Nordisk A/S	4.5%
Zoetis Inc	4.5%
Danaher Corp	4.4%
UnitedHealth Group Inc	4.3%
Thermo Fisher Scientific Inc	4.2%
Intuitive Surgical Inc	4.2%
Pfizer Inc	4.1%
IQVIA Holdings Inc	4.1%
Steris plc	4.1%
Straumann Holding AG	4.1%
Edwards Lifesciences Corp	4.1%
Merck KGaA	3.9%
West Pharmaceutical Services Inc	3.9%
HCA Healthcare Inc	3.8%
IDEXX Laboratories Inc	3.8%
Abbott Laboratories	3.7%
Eli Lilly and Co	3.4%
Abbvie Inc	3.3%
AstraZeneca PLC	3.3%
Laboratory Corporation of America Holdings	3.3%
Johnson & Johnson	3.3%
Charles River Laboratories International Inc	2.5%
Avantor Inc	2.4%
GlaxoSmithKline PLC	2.4%
Mettler-Toledo International Inc	2.0%
Total	91.6%

The investment portfolio may change due to ongoing portfolio transactions of the investment fund. Quarterly updates are available within 60 days of each quarter end.